RT Journal Article SR Electronic T1 52 Application of HPV integration test among HPV-positive women after cervical conization: an observational cohort study JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A75 OP A75 DO 10.1136/ijgc-2024-ESGO.124 VO 34 IS Suppl 1 A1 Lin, Wenyu A1 binhua Dong, Binhua Lin A1 Sun, Pengming YR 2024 UL http://ijgc.bmj.com/content/34/Suppl_1/A75.2.abstract AB Introduction/Background HPV DNA integration into the host genome is considered one of the most important risk factors for cervical carcinoma development. Therefore, the study aimed to identify the integration sites and evaluate the association between HPV integration and lesion regression in HPV-positive women after cervical conization.Methodology A total of 48 HPV-positive women after cervical conization were enrolled in this study. They underwent routine cervical cancer screening (including PCR-RDB HPV genotyping test, cytology tests) and HPV integration test. Colposcopy and biopsy were performed if any abnormal results were present.Results Of the 48 women included in the study, a total of 7 (14.58%) cases were HPV integration positive. HPV 16-positive patients consistently had the highest HPV integration reads (n = 171) as compared to patients with other HPV subtypes, followed by HPV (52, 59, 35, 39). There were 10 kinds of integration genes, including the ZNF670-ZNF695 gene (ncRNA-intronic), CCK (intergenic), LYZL4 (intergenic), TRIML1 (intergenic), LINC01060 (intergenic), PTPRD (intronic), TLR4 (intergenic), LINC02578 (intergenic), USP10 (intron), and GABARAPL2 (intronic). At the end of 12 months, age ≥40 years (P=0.017), and HPV integration (P=0.044) were risk factors for residual lesions in HPV-positive women after cervical conization.Conclusion HPV 16-positive patients had the highest HPV integration reads. HPV integration was the risk factor for residual lesions in HPV-positive women after cervical conization. The integration hot spots identified in our study may be used as biomarkers for early personalized triage of patients with HPV integration after cervical surgery.Disclosures None.